
Indivior PLC (INDV) Stock Forecast & Price Target
Indivior PLC (INDV) Analyst Ratings
Bulls say
Indivior PLC has demonstrated robust growth in its product line, with units dispensed escalating by 19% from the previous quarter, and a notable increase of 37% in patients on Sublocade treatment year-over-year, signaling strong demand in the market. The company's strategic emphasis on expanding the Sublocade network saw a remarkable 60% increase in injections at alternate sites of care, further enhancing accessibility and patient outreach. With projected sales for Sublocade reaching $820M-$880M for 2024 and an attractive valuation at only ~3x EV/2025 EBITDA amidst a clear growth trajectory, the overall risk/reward profile for Indivior's stock appears compelling.
Bears say
Indivior PLC's revenue guidance for 2024 has been reduced to a range of $725 million to $745 million for Sublocade, indicating a downward revision due to competitive pressures from Braeburn's Brixadi and inventory challenges. Additionally, the company's expectations for annual sales growth have been diminished, reflecting a lower anticipated growth rate of 17% compared to 2023, down from previously expected growth rates. The altered outlook is compounded by headwinds related to Medicaid disenrollments, suggesting a concerning trend in both market dynamics and operational execution that may hinder future profitability.
This aggregate rating is based on analysts' research of Indivior PLC and is not a guaranteed prediction by Public.com or investment advice.
Indivior PLC (INDV) Analyst Forecast & Price Prediction
Start investing in Indivior PLC (INDV)
Order type
Buy in
Order amount
Est. shares
0 shares